User:MDElliottMD/Sandbox/CYP2C9: Revision history

Nav

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

curprev 22:3922:39, 19 May 2026 MDElliottMD talk contribs 66 bytes −21,014 Redirect to canonical enzyme sandbox location. This User: page was a cross-session sandbox-location duplication artifact; the canonical enzyme sandbox pages live under Pharmacopedia:Pharmacogenomics sandbox/Enzyme <NAME>. Content (full retrofitted version) is preserved at the canonical title. Tag: New redirect
curprev 20:1320:13, 19 May 2026 MDElliottMD talk contribs 21,080 bytes +14 Expand CYP2C9 substrate section per Mark 2026-05-19 Option C decision: replace bullet list with 36-row sortable wikitable (substrate / therapeutic class / CYP2C9 contribution tier / clinical notes) covering anticoagulants, antiepileptics, NSAIDs, sulfonylureas, ARBs, statins, cannabinoids, antifungals, others. Add Comprehensive-tables pointer section naming Flockhart Indiana University table, FDA Drug Development table, PharmGKB (cited Whirl-Carrillo 2021 PMID 34216021). Add Zanger and Schwab...
curprev 20:0820:08, 19 May 2026 MDElliottMD talk contribs 21,066 bytes +67 Expand CYP2C9 substrate section per Mark 2026-05-19 Option C decision: replace bullet list with 36-row sortable wikitable (substrate / therapeutic class / CYP2C9 contribution tier / clinical notes) covering anticoagulants, antiepileptics, NSAIDs, sulfonylureas, ARBs, statins, cannabinoids, antifungals, others. Add Comprehensive-tables pointer section naming Flockhart Indiana University table, FDA Drug Development table, PharmGKB (cited Whirl-Carrillo 2021 PMID 34216021). Add Zanger and Schwab...
curprev 20:0120:01, 19 May 2026 MDElliottMD talk contribs 20,999 bytes +123 Expand CYP2C9 substrate section per Mark 2026-05-19 Option C decision: replace bullet list with 36-row sortable wikitable (substrate / therapeutic class / CYP2C9 contribution tier / clinical notes) covering anticoagulants, antiepileptics, NSAIDs, sulfonylureas, ARBs, statins, cannabinoids, antifungals, others. Add Comprehensive-tables pointer section naming Flockhart Indiana University table, FDA Drug Development table, PharmGKB (cited Whirl-Carrillo 2021 PMID 34216021). Add Zanger and Schwab...
curprev 19:5019:50, 19 May 2026 MDElliottMD talk contribs 20,876 bytes +7,014 Expand CYP2C9 substrate section per Mark 2026-05-19 Option C decision: replace bullet list with 36-row sortable wikitable (substrate / therapeutic class / CYP2C9 contribution tier / clinical notes) covering anticoagulants, antiepileptics, NSAIDs, sulfonylureas, ARBs, statins, cannabinoids, antifungals, others. Add Comprehensive-tables pointer section naming Flockhart Indiana University table, FDA Drug Development table, PharmGKB (cited Whirl-Carrillo 2021 PMID 34216021). Add Zanger and Schwab...
curprev 19:3119:31, 19 May 2026 MDElliottMD talk contribs 13,862 bytes +13,862 Sandbox-save CYP2C9 enzyme entity page (4th of 10 pharmacogenomics enzyme pages). History-first spine: Rettie 1992 Seattle / S-warfarin / CYP2C9. Three CPIC guidelines cited: warfarin 2017 PMID 28198005, phenytoin 2020 PMID 32779747, NSAIDs 2020 PMID 32189324. Plus Rettie 1992 PMID 1581537, Sullivan-Klose 1996 PMID 8873220 (CYP2C9*3 / tolbutamide), Aithal 1999 PMID 10073515 (Lancet warfarin dose / bleeding). All 6 PMIDs NCBI-eutils-verified. Final home Enzyme:CYP2C9 once namespace registered.

19 May 2026